


AMENDED CLAIM SET:

1. (currently amended) A 1,4-diazabicycloalkane compound of Formula IV:



any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically-acceptable addition salt thereof, or an N-oxide thereof, wherein n is 1, 2 or 3; X represents O or S; and Ar represents an aryl group selected from phenyl and naphthyl, or a heteroaryl group selected from furanyl, thiienyl and pyridinyl, which aromatic group may optionally be substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, alkenyl, alkynyl, alkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alcoxy, halogen, CF₃, CN, NO₂, NH₂, carboxy, carbamoyl, amido, sulfamoyl, phenyl and benzyl.

2. (previously presented) The compound of claim 1, wherein Ar may optionally be substituted one or more times with substituents selected from the group consisting of alkyl, alkoxy, halogen, CF₃, CN, NO₂, NH₂ and phenyl.

3. – 6. (cancelled).

7. (previously presented) The compound of claim 1, wherein Ar represents phenyl, optionally substituted one or two times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, alkoxy, cycloalkoxy, halogen, CF₃, CN, NO₂, NH₂, carboxy, carbamoyl, amido and sulfamoyl.

8. (cancelled).

9. (previously presented) The compound of claim 1, which is

4-[5-Phenyl-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;
4-[5-(3-Methoxyphenyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;
4-[5-(4-Methoxyphenyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;
4-[5-(4-Chlorophenyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;
4-[5-(4-Phenyl-phenyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;
4-[5-(2-Naphthyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;
4-[5-(2-Furyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;
4-[5-(3-Pyridyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;
4-[5-(4-Pyridyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane; or
4-[5-(2-Thienyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;
or an enantiomer or a mixture of enantiomers, or a pharmaceutically-acceptable addition salt thereof, or an N-oxide thereof.

10. - 22. (cancelled).

23. (previously presented) A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1, any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically-acceptable addition salt thereof, together with at least one pharmaceutically-acceptable carrier or diluent.

24. (currently amended) A method of the treatment, prevention or alleviation of a disease or a disorder or a condition of a living animal body, including a human, which disease or disorder is associated with withdrawal symptoms caused by termination of use of tobacco, heroin, cocaine, morphine, benzodiazepines, benzodiazepine-like drugs, or alcohol, which method comprises the step of administering to such a living animal body, including a human, in need thereof a therapeutically effective amount of a compound of claim 1, any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically-acceptable addition salt thereof.

25. – 33. (cancelled).

34. (currently amended) The 4,4-diazabicycloalkane derivative 1,4-diazabicycloalkane compound of claim 1, wherein Ar represents phenyl, optionally substituted one or two times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, alkoxy, cycloalkoxy, halogen, CF₃, CN, NO₂, NH₂, carboxy, carbamoyl, amido, sulfamoyl, phenyl, and benzyl.

35. (currently amended) The 1,4-diazabicycloalkane-derivative 1,4-diazabicycloalkane compound of claim 34, wherein Ar represents phenyl, optionally substituted one or two times with substituents selected from the group consisting of alkyl, alkoxy, halogen, CF₃, CN, NO₂, NH₂, and phenyl.